Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. 196. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572 586. 197. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145 153. 198. Mann JF, Schmieder RE, DyalL,etal. Effectoftelmisartanonrenal outcomes: a randomized trial. Ann Intern Med. 2009;151:1 10. W11 W12. 199. Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005;293:1595 1608. 200. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861 869. 201. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care. 2000;23(suppl 2):B35 B39. 202. Mann JF, Gerstein HC, Yi QL, et al. Progression of renal insuf ciency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis. 2003;42:936 942. 203. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insuf ciency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;(suppl 1):S16 S20. discussion S41 S43. 204. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Int. 1992;41:912 919. 205. Bakris GL, Slataper R, Vicknair N, et al. 